End-stage renal disease in a child with focal segmental glomerulosclerosis associated with a homozygous NUP93 variant

Ratna Acharya | Kiran Upadhyay

Abstract
This report highlights that the genetic causes of FSGS, including NUP93 gene variant, such as the one described in this report, progress to end-stage renal disease rapidly and that the risk of recurrence post-renal transplantation is less likely.

KEYWORDS
child, focal segmental glomerulosclerosis, nephrotic syndrome, NUP93

1 INTRODUCTION
Several podocyte gene variants are associated with steroid-resistant nephrotic syndrome. We describe an 8-year-old girl who presented with nephrotic range proteinuria and was found to be homozygous in the nucleoporin (NUP93) gene for a novel sequence variant. This is the first case report description of such novel variant.

The monogenic causes of nephrotic syndrome (NS) are a rapidly evolving field with the discovery of new podocyte genes. These podocytopathies account for about one-quarter of pediatric steroid-resistant nephrotic syndrome (SRNS) cases.1 Also, unlike immune-mediated NS, most patients with inherited podocytopathies are more likely to have rapid progression to end-stage renal disease (ESRD).2 The gene affected and the type of variant strongly determine the age at first presentation and the rate of disease progression.2 Hence, a genetic diagnosis is helpful not only for better understanding of the disease but also to assess therapeutic success of immunosuppressive agents, and to predict the risk of recurrence after transplantation.3

Nucleoporins (NUP) are nuclear envelope proteins that form the nuclear pore complex (NPC) and are located in the inner (NUP93 and NUP205) and outer (NUP85, NUP107, NUP133, and NUP160) ring of the NPC. NUPs play roles in the nucleocytoplasmic transport, SMAD signaling, chromatin organization, regulation of gene expression, and DNA repair.4 Recently, a few cases of SRNS due to NUP93 variants have been reported.5,6 Here, we report a homozygous NUP93 novel sequence variant in an Indian child with focal segmental glomerulosclerosis (FSGS) leading to rapidly progressive ESRD. This variant is predicted to result in the amino acid substitution p. Ile714Thr and has not been reported in literature or public databases.
CASE PRESENTATION

A previously healthy eight-year-old girl who was born in India and migrated to the United States at four years of age presented with hypertensive urgency and nephrotic range proteinuria (urine protein ≥ 300 mg/dl and spot urine protein to creatinine ratio of 14 mg/mg). She was asymptomatic besides headaches. Urine output was normal, and there was no history of facial puffiness or swelling of feet or abdomen. There was no history of usage of non-steroidal anti-inflammatory drugs and other nephrotoxic agents, dehydration, and recent infections including urinary tract infections. There were no other known significant past medical problems. She was born full term with no perinatal complications. Family history was significant for consanguinity. On examination, the child was at 75th percentile for height and 55th percentile for weight. Besides strabismus, there was no dysmorphism, periorbital puffiness, ascites, or pedal edema. Gross physical examination of all other organ systems was normal. Pertinent laboratory test showed serum albumin 3.1 gm/dl, blood urea nitrogen 14 mg/dl, and serum creatinine 1.6 mg/dl. Serum total cholesterol was mildly elevated (200 mg/dl) with normal HDL and LDL cholesterol, and normal triglycerides. Blood counts were normal. There was no microscopic hematuria. Serum complements were normal. Antinuclear and anti–double-stranded DNA antibodies were negative. Hepatitis panel, human immunodeficiency virus, and tuberculin test were all negative. Non-contrast computed tomography scan of the head was normal. Renal bladder sonogram showed bilateral echogenic kidneys with right kidney of 8.2 cm (28th percentile for age, 0.58 standard deviation below the mean) and left kidney of 8.7 cm in length (53rd percentile for age, 0.09 standard deviation above the mean) without hydronephrosis. Nasopharyngeal swab for respiratory viruses including SARS-CoV-2 was negative. Echocardiogram showed evidence of mild left ventricular hypertrophy but no other abnormalities.

Serum creatinine over next few days increased to 1.8 mg/dl (Schwartz estimated glomerular filtration rate 32 ml/1.73 m²/min). Serum intact parathyroid hormone was 217 pg/ml and there was mild iron deficiency. Nephrotic range proteinuria persisted but the spot urine protein to creatinine ratio decreased to values ranging from 5 to 7 mg/mg after addition of lisinopril. To determine the acute versus chronic nature of her kidney disease and for diagnostic evaluation of the nephrotic range proteinuria and elevated serum creatinine, a percutaneous renal biopsy was performed which showed 18 out of 20 globally sclerotic glomeruli. One glomerulus showed segmental sclerosis without collapse in majority of glomerular capillary tuft, associated with podocyte hyperplasia and foam cells. There was severe interstitial fibrosis and tubular atrophy (IF/TA). Electron microscopy showed partial foot processes effacement detected by Electron microscopy (Direct Mag: 8,000).

![Renal biopsy findings: (A) A majority of glomeruli are globally sclerotic by light microscopy (H&E stain 10× 10). (B) One of remaining viable glomerulus shows normal in mesangial cellularity and matrix (H&E stain 40× 10). (C) Another glomerulus has sclerosis in more than half of glomerulus capillary tuft, associated with podocyte hyperplasia (H&E stain 40× 10). (D) Podocyte foot processes effacement detected by Electron microscopy (Direct Mag: 8,000).](image)
Due to the elevated serum creatinine and features of advanced chronic kidney disease in the biopsy, it was likely that the child will require dialysis and/or kidney transplantation in the future. Hence, a genetic testing was performed to determine the genetic risk of recurrence post-transplantation, and to assess whether immunosuppressive therapy is warranted to manage the nephrotic proteinuria. A combination of next-generation sequencing (NGS) and sanger sequencing was done to cover the full coding regions of the 72 genes known to cause NS/FSGS along with ~10 bases of non-coding DNA flanking each exon (Prevention Genetics, Marshfield, WI, USA). The test showed the patient to be heterozygous in the ACTN4 (NM_004924.5), INF2 (NM_022489.3), and KANK1 (NM_015158.3) genes for three novel sequence variants of uncertain significance (c.158G>T, c.3632G>T, and c.2884G>A, respectively). None of these variants are listed in the ClinVar. She was also found to be homozygous in the NUP93 (NM_014669.4) gene for a novel sequence variant c.2141T>C, which is predicted to result in substitution, transition, missense point mutation leading to replacement of protein isoleucine by protein threonine (p. Ile714Thr) (Table 1). This variant is also not listed in the ClinVar. There were no copy number variants detected within the genomic regions of this test with a sensitivity approaching 100%. Although ~10 bases of non-coding DNA flanking each exon were analyzed by this test, the deep introns were not analyzed. No further in vitro functional studies were performed; and hence, the exact functional implications of these variants were unknown. However, to determine the pathogenicity of these variants, in silico tests were performed using SIFT (Sorting Intolerant From Tolerant), FATHMM (Functional Analysis Through Hidden Markov Models), PolyPhen-2 (Polymorphism Phenotyping V-2), and MutationTaster. The resulted predictions utilizing these in silico tools for these four variants were “conflicting” for ACTN4, INF2, and NUP93 and “tolerated” for KANK1 (Table 1). Both parents were also heterozygous carriers of this NUP93 sequence variant and did not have proteinuria. Similarly, targeted testing of ACTN4 and INF2 genes of parents showed that father was heterozygous in the ACTN4 and INF2 genes for familial variants of uncertain significance (VUS) designated c.158G>T and c.3632G>T (in silico prediction “conflicting” for both variants), respectively (same as the child). Mother was also heterozygous in the ACTN4 gene for a familial sequence VUS designated c.158G>T (in silico prediction “conflicting,” same as the child), but did not have the sequence variant INF2 c.3632G>T (p. Arg1211Leu), as seen in the father and child. There were no other family members with the same condition. Due to inherited gene variants and likelihood of steroid resistance, she was not treated with steroid or immunosuppressive agents.

**TABLE 1** Molecular genetics report of Nephrotic syndrome/Focal segmental glomerulosclerosis panel of the patient

| Gene      | Transcript | Mode of inheritance | DNA variations, predicted effects | Mode in silico Missense Predictions | Interpretation | ClinVar ID | Highest allele frequency in a gnomAD population |
|-----------|------------|---------------------|-----------------------------------|--------------------------------------|----------------|------------|-----------------------------------------------|
| ACTN4     | NM_004924.5| AD, 604638           | c.158G>T, p. Arg53Leu             | Heterozygous                         | Conflicting    | Undocumented | 0.0057%, South Asian                        |
| INF2      | NM_022489.3| AD, 61098.2          | c.3632G>T, p. Arg1211Leu          | Heterozygous                         | Conflicting    | Undocumented | 0.06%, South Asian                          |
| KANK1     | NM_015158.3| AR, 607704           | c.2884G>A, p. Ala962Thr           | Heterozygous                         | Tolerated      | Undocumented | 0.004%, European (Non-Finnish)               |
| NUP93     | NM_014669.4| AR, 614351           | c.2141T>C, p. Ile714Thr           | Homozygous                           | Conflicting    | Homozygous | Not present                                  |

Note: ClinVar ID: Variant accession (www.ncbi.nlm.nih.gov/clinvar); gnomAD: Allele frequency registered in a large population database (gnomad.broadinstitute.org); value listed is the highest allele frequency reported within one of seven population categories recognized in gnomAD V.2.0. Missense Predictions: Summarized output (Damaging, Conflicting, or Tolerated via Polyphen-2, SIFT, MutationTaster, and FATHMM).

Abbreviations: AD, autosomal dominant; AR, autosomal recessive.
Hypertension was managed with lisinopril, amlodipine, and labetalol with stabilization of blood pressures. She subsequently progressed to ESRD ten months later and was started initially on chronic hemodialysis followed by peritoneal dialysis. She received a deceased donor renal transplant 14 months later with no occurrence of recurrent disease during her most recent follow-up six months post-transplant. Her maintenance immunosuppression consisted of tacrolimus, mycophenolate, and prednisone.

3 | DISCUSSION

Steroid-resistant nephrotic syndrome is the second most common cause of ESRD in children and young adults. About 15%–20% of all idiopathic pediatric NS are steroid resistant with prognosis varying from permanent remission to progression to ESRD. SRNS could be either immune-mediated or secondary to podocyte gene variants. More than 50 monogenic causes of SRNS have been described so far. Sadowski et al. showed that monogenic podocytopathies were found in about one-third of pediatric SRNS. In this study, a single-gene variant was found in 29.5% of children and young adults with the highest detection in those with SRNS onset in the first three months of life (69.4%) and least if the onset was between 13 and 18 years of age (10.8%). A causative variant was found in 49.5% of consanguineous families but in only 25% of non-consanguineous families. Nucleoporin 93 (NUP93) was not tested in this study. Our patient was born to consanguineous parents of Indian origin and presented at eight years of age with nephrotic range proteinuria and was homozygous in the NUP93 gene for a novel sequence VUS along with heterozygous in the ACTN4, KANK1, and INF2 genes for novel sequence VUS. Hence, this report adds a novel NUP93 variant to the genetic spectrum in Indian children with SRNS.

Variants in nucleoporin NUP93 were recently described as one of the causes of SRNS which can cause rapidly progressive ESRD. Braun et al. studied 7 individuals with SRNS (Serbian, German, and Turkish descent) due to recessive NUP93 variants but none of these individuals had the variant described in this report. FSGS was the predominant renal histology and one had diffuse mesangial sclerosis. Hematuria was present in some patients; one had Marcus-Gunn syndrome and rest had no extra-renal manifestations. One patient responded partially to steroid, and two responded partially to cyclosporin. The age of onset was 1–6 years of age and ESRD occurred at 1–11 years. NUP93 variant was shown to disrupt NPC assembly and to prevent NUP93 interaction with the signaling protein SMAD4. Bezdíčka et al. reported a 5.4% incidence of NUP93 variant in children with SRNS from Czech Republic and Slovakia. Seeman et al. reported recurrent FSGS post-transplant in a 7-year-old child with NUP93 variant. This is in contrast with the common observation of less likelihood of disease recurrence post-transplant in vast majority of patients with SRNS due to inherited gene mutations. Sandokji et al. reported a 5-year-old non-consanguineous female of African American and Hispanic origin with NUP93 variant resulting in ESRD and renal transplant with no recurrence. We identified a homozygous NUP93 novel sequence variant in a consanguineous Indian girl who had a rapidly progressive ESRD in the first decade of life with no disease recurrence in the post-transplant period.

Variants of the outer ring subunit proteins of the NPC can also cause SRNS. Park et al. described Korean children with SRNS caused by NUP107 variants; all had an earlier onset of NS and more rapid progression to ESRD compared with variant-negative patient. None of these patients had recurrence of disease after renal transplantation. Braun et al. identified recessive variants in four genes encoding the components of the outer ring subunits of the NPC among 29 individuals of 13 consanguineous families. FSGS was the primary renal histology. Some of them had extra-renal manifestations such as short stature, microcephaly, and skeletal/facial phenotypes. The authors showed that knockout of NUP85, NUP107, or NUP133 genes in podocytes activated Cdc42 and increased the formation of filopodia which impaired the actin cytoskeleton. Indeed, the dysregulation of the Cdc42 causes impairment of the actin dynamics which plays an important role in the pathogenesis of monogenic SRNS.

Our patient also was heterozygous in the KANK1 gene for a novel variant. Variants in KANK family genes can lead to podocyte dysfunction and autosomal recessive form of NS. Other heterozygous VUS that were found in our patient were in the INF2 and ACTN4 genes; variants affecting function of these genes are well-known causes of autosomal dominant (AD) SRNS. Although variants affecting functions of ACTN4 and INF2 are transmitted as AD; and hence, heterozygous variants could be potentially causal, the parents who carried the same heterozygous variants of ACTN4 and INF2 were asymptomatic without any proteinuria. Hence, given that the child was homozygous for the NUP93 variant for which parents were heterozygous, the possibility of this NUP93 variant leading to the nephrotic proteinuria was more likely. However, all of these variants in these genes were reported as VUS; and hence, it is difficult to establish a definite causal relationship between the variant gene and the clinical manifestation. Hence, when such novel variants are reported in a disease context, functional studies, if performed, provide valuable information on how these variants affect the protein function.
and contribute to the disease phenotype. In our patient, although the functional studies were not performed, in silico analyses were performed in an order to predict the impact of these novel variants in the outcome. However, given the low specificities of these in silico prediction tools, they may not be suitable to predict the pathogenicity of VUS. Hence, it is difficult to derive clinical consequences based solely on in silico predictions. However, one study suggested that these tools could be suitable to predict benignity. Also, with the advancement of technologies in genetic testing such as NGS, the probability of identification of multiple novel variants in more than one gene is also high. Hence, it is important to interpret the significance of these variants taking into consideration the clinical manifestations, laboratory data, and family history, especially in those with chronic kidney disease of unknown etiology. Our report also indicates that patients carrying variants in multiple SRNS genes may have more severe disease phenotype, in concordance with prior reported studies. Lastly, variants in genes not analyzed in this study could be causative of FSGS in this consanguineous girl. Also, since the deep introns were not analyzed, there is a possibility of missing deep intronic variants which have been shown to be associated with FSGS.

4 | CONCLUSIONS

The discovery of novel genes and their sequence variants in NS helps us understand the molecular mechanisms of disease and predict the disease course and severity. Reports of other cases of NUP93 variants are needed to improve our understanding of the exact mechanism of podocyte injury in these patients.

ACKNOWLEDGEMENT

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

RA and KU contributed to conception and design of the study, acquisition and analysis of data, literature review, and drafting the whole manuscript.

ETHICAL APPROVAL

We testify that: This material has not been published in whole or in part elsewhere; The manuscript is not currently being considered for publication in another journal; We have been personally and actively involved in substantive work leading to the writing of this manuscript and will hold ourselves jointly and individually responsible for its content.

CONSENT

Written informed consent was obtained from the parent to use the data and publish this report in accordance with journal’s patient consent policy.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Kiran Upadhyay https://orcid.org/0000-0002-8441-0220

REFERENCES

1. Trautmann A, Bodria M, Ozaltin F, et al. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin J Am Soc Nephrol. 2015;10(4):592-600.
2. Trautmann A, Lipska-Ziętkiewicz BS, Schaefer F. Exploring the clinical and genetic spectrum of steroid resistant nephrotic syndrome: the PodoNet registry. Front Pediatr. 2018;17(6):200.
3. Niaudet P. Genetic forms of nephrotic syndrome. Pediatr Nephrol. 2004;19(12):1313-1318.
4. Beck M, Hurt E. The nuclear pore complex: understanding its function through structural insight. Nat Rev Mol Cell Biol. 2017;18(2):73-89.
5. Braun DA, Sadowski CE, Kohl S, et al. Mutations in nuclear pore genes NUP93, NUP205 and XPO5 cause steroid-resistant nephrotic syndrome. Nat Genet. 2016;48(4):457-465.
6. Bezdička M, Štolbová Š, Seeman T, et al. Genetic diagnosis of steroid-resistant nephrotic syndrome in a longitudinal collection of Czech and Slovak patients: a high proportion of causative variants in NUP93. Pediatr Nephrol. 2018;33(8):1347-1363.
7. Sadowski CE, Lovric S, Ashraf S, et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2015;26(6):1279-1289.
8. Seeman T, Vondrak K. First report of recurrent nephrotic syndrome after kidney transplantation in a patient with NUP93 gene mutations: a case report. Transplant Proc. 2018;50(10):3954-3956.
9. Sandokji I, Marquez J, Ji W, et al. Identification of novel mutations and phenotype in the steroid resistant nephrotic syndrome gene NUP93: a case report. BMC Nephrol. 2019:20(1):271.
10. Park E, Ahn YH, Kang HG, Miyake N, Tsukaguchi H, Cheong HI. NUP107 mutations in children with steroid-resistant nephrotic syndrome. Nephrol Dial Transplant. 2017;32(6):1013-1017.
11. Braun DA, Lovric S, Schapiro D, et al. Mutations in multiple components of the nuclear pore complex cause nephrotic syndrome. J Clin Invest. 2018;128(10):4313-4328.
12. Zhao F, Zhu JY, Richman A, et al. Mutations in NUP160 are implicated in steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2019;30(5):840-853.
13. Gee HY, Saisawat P, Ashraf S, et al. ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling. *J Clin Invest*. 2013;123(8):3243-3253.

14. Gee HY, Zhang F, Ashraf S, et al. KANK deficiency leads to podocyte dysfunction and nephrotic syndrome. *J Clin Invest*. 2015;125(6):2375-2384.

15. Ernst C, Hahnen E, Engel C, et al. Performance of in silico prediction tools for the classification of rare BRCA1/2 missense variants in clinical diagnostics. *BMC Med Genomics*. 2018;11(1):35.

16. Richards S, Aziz N, Bale S, et al. ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17(5):405-424.

17. Bullich G, Trujillano D, Santín S, et al. Targeted next-generation sequencing in steroid-resistant nephrotic syndrome: mutations in multiple glomerular genes may influence disease severity. *Eur J Hum Genet*. 2015;23(9):1192-1199.

18. Rossanti R, Shono A, Miura K, et al. Molecular assay for an intronic variant in NUP93 that causes steroid resistant nephrotic syndrome. *J Hum Genet*. 2019;64(7):673-679.

How to cite this article: Acharya R, Upadhyay K. End-stage renal disease in a child with focal segmental glomerulosclerosis associated with a homozygous NUP93 variant. *Clin Case Rep*. 2021;9:e05111. [https://doi.org/10.1002/ccr3.5111](https://doi.org/10.1002/ccr3.5111)